MT-RNR1 POCT
Point-of-care molecular testing (POCT) of MT-RNR1 for avoidance of aminoglyocside induced hearling loss in neonates (Artificial Buccal swabs)
Overview
The scheme is designed to assess the analytical process (genotyping) only.
At a glance
Product Code:
07-POCT-MTRNR1-27
Target/Genes:
The MT-RNR1 m.1555A>G variant associated with aminoglycoside induced hearing loss in neonates
Technology:
PCR based
Sample Type:
Artificial Buccal Swab
Submit Results In:
Not applicable
Accredited:
No
Key Dates
22/10/2027
Every 3 months
4 weeks after sample dispatch
Sample Details
EQA Results
The user will receive a survey report containing device specific performance data, benchmarked against the cohort of participating users. Additionally a annual report summarising the years data will also be provided.
Participation Information
Point-of-Care testing for the MT-RNR1 m.1555A>G variant.
Users will receive two EQA samples every three months (8 samples per year), allowing them to verify the ongoing accuracy of MT-RNR1 testing on their POCT devices, to ensure patients receive the most reliable diagnoses possible.
Users are required to report MT-RNR1 m.1555A>G detection status, with additional patient identifiers.
Additional samples are available to purchase for device verification. You can purchase a verification package of materials from our website by navigating to the ‘EQA Scheme catalogue’ section, selecting Point of Care Testing.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
Send your enquiry by submitting the form
Closes in 347 days
From £1200.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.